Biofrontera (NASDAQ:BFRIW – Get Free Report) is anticipated to issue its results before the market opens on Wednesday, November 18th. Analysts expect the company to post earnings of ($0.22) per share and revenue of $8.25 million for the quarter.
Biofrontera Stock Performance
BFRIW opened at $0.00 on Wednesday. Biofrontera has a 12 month low of $0.00 and a 12 month high of $0.15. The stock’s 50 day moving average price is $0.01 and its 200 day moving average price is $0.03.
About Biofrontera
Biofrontera Inc. is a biopharmaceutical company focused on dermatology. It develops and commercializes treatments for sun-damaged skin and other conditions, with an emphasis on photodynamic therapy, which uses a light-sensitive medicine activated by a light source. Biofrontera Inc. became a separately traded U.S. company after its separation from Germany-based Biofrontera AG. BFRIW represents warrants associated with Biofrontera Inc., rather than the company’s common stock.
Further Reading
- Five stocks we like better than Biofrontera
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
